Voleon Capital Management LP Raises Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Voleon Capital Management LP increased its holdings in Regeneron Pharmaceuticals by 85.4% during the first quarter, reaching a total of 1,244 shares worth $789,000.
• Multiple hedge funds have drastically increased their stakes in Regeneron, with GAMMA Investing LLC raising its position by an astounding 89,825.0%, now owning 815,620 shares valued at $517.3 million.
• Regeneron reported a strong earnings performance with $12.89 EPS for the quarter, significantly beating analyst estimates and showing a 3.6% year-over-year revenue increase.

Voleon Capital Management LP grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 85.4% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,244 shares of the biopharmaceutical company's stock after purchasing an additional 573 shares during the period. Voleon Capital Management LP's holdings in Regeneron Pharmaceuticals were worth $789,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Nuveen LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $343,764,000. Pacer Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after acquiring an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after acquiring an additional 226,952 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $8.20 on Friday, hitting $560.00. 602,540 shares of the stock traded hands, compared to its average volume of 942,825. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,170.58. The business's fifty day moving average is $564.61 and its two-hundred day moving average is $578.77. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The firm has a market capitalization of $59.35 billion, a price-to-earnings ratio of 14.11, a PEG ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the previous year, the company posted $11.56 EPS. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is presently 8.87%.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent analyst reports. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Jefferies Financial Group upped their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a report on Wednesday, August 27th. Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price objective for the company. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a report on Monday, August 4th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.